109 related articles for article (PubMed ID: 16758749)
1. [Entecavir--close perspective for using it].
Halota W; Pawłowska M
Przegl Epidemiol; 2006; 60(1):115-8. PubMed ID: 16758749
[TBL] [Abstract][Full Text] [Related]
2. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Sims KA; Woodland AM
Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
[TBL] [Abstract][Full Text] [Related]
3. Entecavir for chronic hepatitis B: a review.
Palumbo E
Ther Drug Monit; 2008 Feb; 30(1):1-4. PubMed ID: 18223455
[TBL] [Abstract][Full Text] [Related]
4. A review of entecavir in the treatment of chronic hepatitis B infection.
Rivkin A
Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706
[TBL] [Abstract][Full Text] [Related]
5. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
6. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
7. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
[TBL] [Abstract][Full Text] [Related]
9. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
[No Abstract] [Full Text] [Related]
11. Entecavir: new drug. Chronic hepatitis B: a last resort.
Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822
[TBL] [Abstract][Full Text] [Related]
12. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
13. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
Zoulim F
Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
[No Abstract] [Full Text] [Related]
15. Chronic hepatitis B: a wider range of therapeutic options.
Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
17. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
[TBL] [Abstract][Full Text] [Related]
18. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
19. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
20. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
Suzuki F; Akuta N; Suzuki Y; Yatsuji H; Sezaki H; Arase Y; Kawamura Y; Hosaka T; Kobayashi M; Ikeda K; Kobayashi M; Watahiki S; Kumada H
J Clin Virol; 2007 Jun; 39(2):149-52. PubMed ID: 17442615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
